Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)

On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

doi:10.1007/s12072-022-10446-0

Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)

On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

Internal Medicine （3）

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

The Figs. 2 and 3 were erroneously labeled in the original publication of the article. ‘ALF score’ should be corrected as ‘mALF score’. The Figs. 2 and 3 should have appeared as shown below.

Original language	English
Pages (from-to)	271-273
Number of pages	3
Journal	Hepatology International
Volume	17
Issue number	1
DOIs	https://doi.org/10.1007/s12072-022-10446-0
State	Published - 2023/02

ASJC Scopus subject areas

Hepatology

Access to Document

10.1007/s12072-022-10446-0

Fingerprint

Dive into the research topics of 'Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)'. Together they form a unique fingerprint.

Cite this

On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) (2023). Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8). Hepatology International, 17(1), 271-273. https://doi.org/10.1007/s12072-022-10446-0

On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). / Correction to : Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8). In: Hepatology International. 2023 ; Vol. 17, No. 1. pp. 271-273.

@article{462f04a48dbe4180a5720ea5d28a3c3f,

title = "Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)",

abstract = "The Figs. 2 and 3 were erroneously labeled in the original publication of the article. {\textquoteleft}ALF score{\textquoteright} should be corrected as {\textquoteleft}mALF score{\textquoteright}. The Figs. 2 and 3 should have appeared as shown below.",

author = "{On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)} and Takeshi Hatanaka and Satoru Kakizaki and Atsushi Hiraoka and Toshifumi Tada and Masashi Hirooka and Kazuya Kariyama and Joji Tani and Masanori Atsukawa and Koichi Takaguchi and Ei Itobayashi and Shinya Fukunishi and Kunihiko Tsuji and Toru Ishikawa and Kazuto Tajiri and Hironori Ochi and Satoshi Yasuda and Hidenori Toyoda and Chikara Ogawa and Takashi Nishimura and Noritomo Shimada and Kazuhito Kawata and Hisashi Kosaka and Takaaki Tanaka and Hideko Ohama and Kazuhiro Nouso and Asahiro Morishita and Akemi Tsutsui and Takuya Nagano and Norio Itokawa and Tomomi Okubo and Taeang Arai and Michitaka Imai and Atsushi Naganuma and Yohei Koizumi and Shinichiro Nakamura and Masaki Kaibori and Hiroko Iijima and Yoichi Hiasa and Takashi Kumada",

note = "Publisher Copyright: {\textcopyright} 2022 Asian Pacific Association for the Study of the Liver.",

year = "2023",

month = feb,

doi = "10.1007/s12072-022-10446-0",

language = "英語",

volume = "17",

pages = "271--273",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer",

number = "1",

}

On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) 2023, 'Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)', Hepatology International, vol. 17, no. 1, pp. 271-273. https://doi.org/10.1007/s12072-022-10446-0

Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8). / On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).
In: Hepatology International, Vol. 17, No. 1, 02.2023, p. 271-273.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)

AU - On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

AU - Hatanaka, Takeshi

AU - Kakizaki, Satoru

AU - Hiraoka, Atsushi

AU - Tada, Toshifumi

AU - Hirooka, Masashi

AU - Kariyama, Kazuya

AU - Tani, Joji

AU - Atsukawa, Masanori

AU - Takaguchi, Koichi

AU - Itobayashi, Ei

AU - Fukunishi, Shinya

AU - Tsuji, Kunihiko

AU - Ishikawa, Toru

AU - Tajiri, Kazuto

AU - Ochi, Hironori

AU - Yasuda, Satoshi

AU - Toyoda, Hidenori

AU - Ogawa, Chikara

AU - Nishimura, Takashi

AU - Shimada, Noritomo

AU - Kawata, Kazuhito

AU - Kosaka, Hisashi

AU - Tanaka, Takaaki

AU - Ohama, Hideko

AU - Nouso, Kazuhiro

AU - Morishita, Asahiro

AU - Tsutsui, Akemi

AU - Nagano, Takuya

AU - Itokawa, Norio

AU - Okubo, Tomomi

AU - Arai, Taeang

AU - Imai, Michitaka

AU - Naganuma, Atsushi

AU - Koizumi, Yohei

AU - Nakamura, Shinichiro

AU - Kaibori, Masaki

AU - Iijima, Hiroko

AU - Hiasa, Yoichi

AU - Kumada, Takashi

PY - 2023/2

Y1 - 2023/2

N2 - The Figs. 2 and 3 were erroneously labeled in the original publication of the article. ‘ALF score’ should be corrected as ‘mALF score’. The Figs. 2 and 3 should have appeared as shown below.

AB - The Figs. 2 and 3 were erroneously labeled in the original publication of the article. ‘ALF score’ should be corrected as ‘mALF score’. The Figs. 2 and 3 should have appeared as shown below.

UR - http://www.scopus.com/inward/record.url?scp=85142118722&partnerID=8YFLogxK

U2 - 10.1007/s12072-022-10446-0

DO - 10.1007/s12072-022-10446-0

M3 - コメント/討論

C2 - 36385371

AN - SCOPUS:85142118722

SN - 1936-0533

VL - 17

SP - 271

EP - 273

JO - Hepatology International

JF - Hepatology International

IS - 1

ER -

On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8). Hepatology International. 2023 Feb;17(1):271-273. doi: 10.1007/s12072-022-10446-0